Delcath surges on FDA fast-track designation
This article was originally published in Clinica
Executive Summary
Shares in high-dose chemotherapy delivery device maker Delcath Systems jumped around 29% last week (May 11), after the firm said its technology for treating metastatic melanoma in the liver with melphalan had received fast-track status from the US FDA.